uploads/2019/05/Graph-2-12-1.png

Comparing TEVA’s and ENDP’s Revenue Growth Trends in 2019

By

Updated

Revenue guidance

In its first-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) reiterated its revenue guidance of $17.0 billion–$17.4 billion and its operating income guidance of $3.8 billion–$4.2 billion for 2019.

Ajovy and Austedo are Teva’s key growth drivers in 2019. Copaxone, however, is expected to report an increased level of generic erosion in 2019.

According to its first-quarter earnings conference call, Teva anticipates a stable revenue performance from its global generics business mainly driven by new product launches and strong brands. Its North American generics business reported revenue of $966 million in the first quarter and has averaged quarterly revenues of close to $1.0 billion since the first quarter of 2018. Its European generics business reported revenue of $919 million in the first quarter and has averaged quarterly revenue of close to $900 million since the first quarter of 2018.

In its first-quarter earnings investor presentation, Endo International (ENDP) reiterated its revenue guidance of $2.76 billion–$2.96 billion.

Article continues below advertisement

Wall Street estimates

Analysts expect Teva Pharmaceutical’s revenues to see YoY (year-over-year) changes of -8.93% to $17.17 billion in 2019, 0.26% to $17.22 billion in 2020, and 1.31% to $17.44 billion in 2021. On the other hand, analysts expect Endo International’s revenues to see YoY changes of -2.55% to $2.87 billion in 2019, 1.23% to $2.91 billion in 2020, and 0.21% to $2.91 billion in 2021.

Analysts expect Teva Pharmaceutical’s revenues to see YoY falls of -9.66% to $4.25 billion in the second quarter, -6.41% to $4.24 billion in the third quarter, and -4.04% to $4.37 billion in the fourth quarter of 2019. Analysts also expect Endo International’s revenues to see YoY falls of -2.74% to $695.10 million in the second quarter, -4.13% to $714.67 million in the third quarter, and -5.69% to $741.64 million in the fourth quarter.

 

Advertisement

More From Market Realist